Retrospective Analysis of Chilean and Mexican GI Stromal Tumor Registries: A Tale of Two Latin American Realities
Open Access
- 1 April 2020
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 6 (6), 647-657
- https://doi.org/10.1200/JGO.19.00410
Abstract
PURPOSE Like other malignancies, GI stromal tumors (GIST) are highly heterogeneous. This not only applies to histologic features and malignant potential, but also to geographic incidence rates. Several studies have reported GIST incidence and prevalence in Europe and North America. In contrast, GIST incidence rates in South America are largely unknown, and only a few studies have reported GIST prevalence in Latin America. PATIENTS AND METHODS Our study was part of a collaborative effort between Chile and Mexico, called Salud con Datos. We sought to determine GIST prevalence and patients' clinical characteristics, including survival rates, through retrospective analysis. RESULTS Overall, 624 patients were included in our study. Our results found significant differences between Mexican and Chilean registries, such as stage at diagnosis, primary tumor location, CD117-positive immunohistochemistry status, mitotic index, and tumor size. Overall survival (OS) times for Chilean and Mexican patients with GIST were 134 and 156 months, respectively. No statistically significant differences in OS were detected by sex, age, stage at diagnosis, or recurrence status in both cohorts. As expected, patients categorized as being at high risk of recurrence displayed a trend toward poorer progression-free survival in both registries. CONCLUSION To the best of our knowledge, this is the largest report from Latin America assessing the prevalence, clinical characteristics, postsurgery risk of recurrence, and outcomes of patients with GIST. Our data confirm surgery as the standard treatment of localized disease and confirm a poorer prognosis in patients with regional or distant disease. Finally, observed differences between registries could be a result of registration bias. (c) 2020 by American Society of Clinical OncologyThis publication has 21 references indexed in Scilit:
- Practical Aspects of Risk Assessment in Gastrointestinal Stromal TumorsJournal of Gastrointestinal Cancer, 2014
- Incidence of soft tissue sarcoma and beyondCancer, 2012
- Risk stratification of patients diagnosed with gastrointestinal stromal tumorHuman Pathology, 2008
- Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based studyBMC Cancer, 2007
- Clinicopathologic study of 275 cases of gastrointestinal stromal tumors: the experience at 3 large medical centers in MexicoAnnals of Diagnostic Pathology, 2007
- Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, SpainEuropean Journal Of Cancer, 2007
- Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of Northern NorwayAPMIS, 2006
- Gastrointestinal stromal tumors in Iceland, 1990–2003: The Icelandic GIST study, a population‐based incidence and pathologic risk stratification studyInternational Journal of Cancer, 2005
- KIT-Negative Gastrointestinal Stromal TumorsThe American Journal of Surgical Pathology, 2004
- The Effect of Surgery and Grade on Outcome of Gastrointestinal Stromal TumorsArchives of Surgery, 2001